8-K: Cigna Group Reports Strong Q3 2025, Reaffirms EPS Outlook

The Cigna Group announced strong third quarter 2025 results, with total revenues up 10% and reaffirmed its 2025 adjusted EPS outlook, alongside a new rebate-free pharmacy benefit model.

Summary

• Total revenues for the third quarter 2025 increased 10% to $69.7 billion compared to the third quarter 2024.
• Shareholders net income for the third quarter 2025 was $1.9 billion, or $6.98 per share, significantly up from $0.7 billion, or $2.63 per share, in the third quarter 2024 (which included a one-time non-cash after-tax investment loss of $1.0 billion).
• Adjusted income from operations for the third quarter 2025 was $2.1 billion, or $7.83 per share, compared with $2.1 billion, or $7.51 per share, for the third quarter 2024.
• The company reaffirmed its 2025 outlook for adjusted income from operations of at least $29.60 per share.
• The Cigna Group announced a new rebate-free pharmacy benefit model designed to lower costs, improve transparency, and support local pharmacies.
• Total pharmacy customers at September 30, 2025, increased 4% from December 31, 2024, to 122.5 million.
• Total medical customers at September 30, 2025, decreased 6% from December 31, 2024, to 18.1 million, primarily reflecting the impact of the HCSC transaction.
• Evernorth Health Services adjusted revenues increased 15% and adjusted income from operations, pre-tax, increased 1% relative to the third quarter 2024.
• Cigna Healthcare adjusted revenues decreased 18% relative to the third quarter 2024 (primarily due to the HCSC transaction), but increased 6% excluding the HCSC transaction.
• Cigna Healthcare adjusted income from operations, pre-tax, decreased 12% relative to the third quarter 2024, primarily driven by a higher Medical Care Ratio (MCR).
• The Cigna Healthcare MCR was 84.8% for the third quarter 2025, compared to 82.8% for the third quarter 2024.

Sentiment

Score: 7

Explanation: The company reported strong revenue growth and a significant increase in net income, reaffirmed its full-year EPS outlook, and introduced a strategic new pharmacy benefit model. While Cigna Healthcare experienced some pressure on profitability and medical customer numbers due to the HCSC transaction and higher MCR, the overall consolidated results and outlook are positive, driven by Evernorth's strong performance.

Positives

• Total revenues for the third quarter 2025 increased 10% to $69.7 billion, demonstrating strong top-line growth.
• Shareholders net income for the third quarter 2025 significantly increased to $1.9 billion ($6.98 per share) from $0.7 billion ($2.63 per share) in the prior year, reflecting improved profitability.
• The company reaffirmed its 2025 outlook for adjusted income from operations of at least $29.60 per share, indicating confidence in future performance.
• A new rebate-free pharmacy benefit model was announced, designed to lower costs, improve transparency, and support local pharmacies, which could be a strategic differentiator.
• Total pharmacy customers increased 4% to 122.5 million from December 31, 2024, driven by new sales and expanded relationships.
• Evernorth Health Services reported a 15% increase in adjusted revenues and a 1% increase in adjusted income from operations, pre-tax, showcasing strong segment performance.
• Specialty and Care Services within Evernorth saw adjusted revenues increase 10% and adjusted income from operations, pre-tax, increase 11%, reflecting strong organic growth and increased adoption of biosimilars.
• Excluding the HCSC transaction, Cigna Healthcare adjusted revenues increased 6%, primarily due to premium rate increases to cover expected medical costs.
• The SG&A expense ratio and adjusted SG&A expense ratio improved to 4.8% and 4.6% respectively, for Q3 2025, compared to 5.6% and 5.5% in Q3 2024, reflecting business mix shift.

Negatives

• Adjusted income from operations for the third quarter 2025 decreased 1% relative to the third quarter 2024, primarily driven by lower contributions from Cigna Healthcare.
• Pharmacy Benefit Services adjusted income from operations, pre-tax, decreased 6%, reflecting strategic investments and initiatives to support business growth.
• Cigna Healthcare adjusted revenues decreased 18% relative to the third quarter 2024, primarily reflecting the impact of the HCSC transaction.
• Cigna Healthcare adjusted income from operations, pre-tax, decreased 12% relative to the third quarter 2024, primarily driven by a higher Medical Care Ratio (MCR).
• The Cigna Healthcare MCR was 84.8% for the third quarter 2025, an increase from 82.8% for the third quarter 2024, due to the Individual and Family Plans business and higher stop loss medical costs.
• Total medical customers decreased 6% from December 31, 2024, to 18.1 million, primarily reflecting the impact of the HCSC transaction.

Risks

• Ability to achieve strategic and operational initiatives.
• Ability to adapt to changes in an evolving and rapidly changing industry.
• Ability to compete effectively, differentiate products and services, and maintain or increase market share.
• Price competition, inflation, and other pressures that could compress margins or result in premiums insufficient to cover service costs.
• Potential for actual claims to exceed estimates related to expected medical claims.
• Ability to develop and maintain satisfactory relationships with healthcare payors, physicians, hospitals, other health service providers, producers, and consultants.
• Ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline.
• Changes in the pharmacy provider marketplace or pharmacy networks.
• Changes in drug pricing or industry pricing benchmarks.
• Ability to invest in and properly maintain information technology and other business systems.
• Ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident.
• Risks related to the use of artificial intelligence and machine learning.
• Political, legal, operational, regulatory, economic, and other risks that could affect multinational operations, including currency exchange rates.
• Risks related to strategic transactions and realization of expected benefits, as well as integration or separation difficulties or underperformance.
• Dependence on success of relationships with third parties.
• Risk of significant disruption within operations or among key suppliers or third parties.
• Potential liability in connection with managing medical practices and operating pharmacies, onsite clinics, and other types of medical facilities.
• Substantial level of government regulation over the business and the potential effects of new laws or regulations or changes in existing laws or regulations.
• Uncertainties surrounding participation in government-sponsored programs and providing services to payors who participate in government-sponsored programs.
• The outcome of litigation, regulatory audits, and investigations.
• Compliance with applicable privacy, security, and data laws, regulations, and standards.
• Potential failure of prevention, detection, and control systems.
• Unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates.
• Risks related to a downgrade in financial strength ratings of insurance subsidiaries.
• The impact of significant indebtedness and the potential for further indebtedness in the future.
• Credit risk related to reinsurers.

Future Outlook

The Cigna Group reaffirms its full-year 2025 consolidated adjusted income from operations outlook of at least $29.60 per share. This outlook includes the impact of expected future share repurchases and anticipated 2025 dividends. Segment-specific outlooks include Evernorth Adjusted Income from Operations, Pre-Tax of at least $7,200 million, Cigna Healthcare Adjusted Income from Operations, Pre-Tax of at least $4,125 million, and a Cigna Healthcare Medical Care Ratio of 83.2% to 84.2%.

Management Comments

• "Our strong quarterly results reflect the breadth of our businesses and focused execution on our growth strategy, even in a dynamic environment."
• "We continue to lead positive change and are addressing some of healthcares biggest challenges. Our new market-defining rebate-free pharmacy benefit model will further lower costs and enhance transparency for the benefit of those we serve."

Industry Context

The introduction of a new rebate-free pharmacy benefit model by The Cigna Group (Evernorth) is a significant strategic move in the pharmacy benefit management (PBM) industry. This model aims to address growing concerns about drug costs and transparency, potentially disrupting traditional PBM practices that often rely on rebates from pharmaceutical manufacturers. This initiative could put pressure on competitors to adopt similar transparent models or risk losing clients seeking lower, more predictable drug costs. It aligns with broader industry and regulatory trends pushing for greater transparency and cost control in healthcare, potentially setting a new standard for PBM services.

Stakeholder Impact

• Shareholders: Potential positive impact due to strong financial results, increased net income, reaffirmed EPS outlook, and the inclusion of expected future share repurchases and anticipated 2025 dividends in the outlook.
• Customers (Pharmacy): Potential positive impact from the new rebate-free pharmacy benefit model, which is designed to lower costs and improve transparency.
• Local Pharmacies: Potential positive impact from the new rebate-free pharmacy benefit model, which aims to support them.
• Employees: No direct impact mentioned, but strong company performance generally provides stability and potential for growth.

Next Steps

• Management will host a conference call on October 30, 2025, at 8:30 a.m. ET to review third quarter 2025 results and discuss the full-year 2025 outlook.

Key Dates

Recommendation

The Cigna Group delivered strong Q3 2025 results with robust revenue growth and a significant increase in net income, coupled with a reaffirmed full-year adjusted EPS outlook. The introduction of a new rebate-free pharmacy benefit model is a strategic move that could enhance transparency and potentially drive future growth in Evernorth. However, the Cigna Healthcare segment experienced a decline in adjusted income from operations and an increase in its Medical Care Ratio, partly due to the HCSC divestiture and higher medical costs in certain areas. While the overall outlook is stable, these mixed segment performances suggest a 'hold' position, as the positive strategic initiatives and overall financial strength are balanced by some operational pressures and the impact of the HCSC transaction. Investors should monitor the execution of the new pharmacy model and the performance of the Cigna Healthcare segment in upcoming quarters.

Keywords

Healthcare, Pharmacy Benefit Management, PBM, Health Insurance, Cigna, Evernorth, Financial Results, Q3 2025, Adjusted EPS, Revenue, Medical Care Ratio, MCR, Customer Relationships, Biosimilars, Strategic Initiatives